Myasthenia Gravis (MG)

Myasthenia Gravis (MG) is an autoimmune neuromuscular disorder characterized by the production of antibodies that target components of the neuromuscular junction (NMJ), the point where motor neurons communicate with skeletal muscle fibers. The hallmark of the disease is fluctuating, fatigable muscle weakness — meaning the muscles get progressively weaker with repeated use and partially recover with rest. To understand why this happens, it helps to first understand how normal neuromuscular transmission works.

Normal Neuromuscular Transmission

When a motor neuron fires an action potential, the signal travels down the axon until it reaches the nerve terminal at the neuromuscular junction. The arrival of the action potential opens voltage-gated calcium channels, allowing calcium ions to flow into the terminal. This calcium influx triggers synaptic vesicles — small packets filled with the neurotransmitter acetylcholine (ACh) — to fuse with the presynaptic membrane and release their contents into the synaptic cleft, the narrow gap between the nerve terminal and the muscle fiber.

ACh then crosses the cleft and binds to nicotinic acetylcholine receptors (AChRs) on the postsynaptic membrane of the muscle fiber. These receptors are ligand-gated ion channels: when ACh binds, the channel opens, allowing sodium ions to flow into the muscle cell. If enough receptors are activated, the cumulative sodium influx generates an endplate potential large enough to trigger a muscle fiber action potential, which then propagates along the muscle and initiates contraction.

Under normal conditions, the system has a significant built-in safety margin. The nerve releases more ACh than is strictly necessary, and the muscle expresses more receptors than the minimum needed to reach threshold. Think of it like a classroom where the teacher (motor neuron) speaks loud enough for every student (receptor) to hear clearly, even if a few students aren’t paying attention. There’s room to spare.

After transmission, ACh is rapidly broken down in the synaptic cleft by an enzyme called acetylcholinesterase (AChE), which prevents continuous stimulation of the muscle and allows the system to reset for the next signal.

The Autoimmune Attack

In myasthenia gravis, the immune system produces antibodies that compromise the postsynaptic side of the neuromuscular junction. The most common target is the AChR itself.

1. Anti-AChR Antibodies (~85% of MG patients)

The majority of MG patients produce antibodies directed against the nicotinic acetylcholine receptor. These antibodies cause damage through three main mechanisms:

First, they can directly block the ACh binding site on the receptor, physically preventing acetylcholine from binding and activating the channel. Imagine someone putting tape over the ears of the students in the classroom — the teacher is still speaking at the same volume, but the message isn’t getting through.

Second, they accelerate the internalization and degradation of AChRs through a process called antigenic modulation. When antibodies crosslink two adjacent receptors on the muscle surface, the cell interprets this as a signal to pull the receptors inside and break them down. The muscle is essentially being tricked into removing its own functional receptors at a rate faster than it can replace them.

Third, the antibodies activate the complement system, a part of the innate immune system that tags damaged or foreign material for destruction. Complement activation at the postsynaptic membrane causes direct structural damage to the muscle endplate, flattening the normal folds of the membrane where AChRs are concentrated. This reduces the surface area available for receptor expression and further diminishes the safety margin.

The cumulative result of all three mechanisms is a postsynaptic membrane with fewer functional receptors, simplified architecture, and a widened synaptic cleft. The nerve still releases normal amounts of ACh, but there are no longer enough working receptors to reliably generate a muscle contraction, especially during sustained or repeated activity.

2. Anti-MuSK Antibodies (~5–8% of MG patients)

A smaller subset of patients produce antibodies against muscle-specific kinase (MuSK), a receptor tyrosine kinase that plays a critical role in organizing and maintaining the structure of the neuromuscular junction. MuSK is essential for clustering AChRs at the postsynaptic membrane during development and throughout life. It does this as part of a signaling cascade involving a nerve-derived protein called agrin.

When agrin is released from the nerve terminal, it binds to a receptor called LRP4 on the muscle surface, which then activates MuSK. Activated MuSK triggers downstream signaling through a protein called rapsyn, which physically anchors AChRs in dense clusters directly opposite the nerve terminal. This precise organization is what makes neuromuscular transmission efficient.

Anti-MuSK antibodies disrupt this entire signaling cascade. Without functional MuSK signaling, AChRs fail to cluster properly, and the postsynaptic architecture gradually degrades. Unlike anti-AChR antibodies, anti-MuSK antibodies are predominantly of the IgG4 subclass, which does not activate complement. The damage here is therefore not inflammatory destruction but rather a functional disorganization of the synapse. The classroom analogy shifts: it’s less that the students’ ears are blocked, and more that the students have scattered across the building and are no longer sitting where the teacher is speaking.

Anti-MuSK MG tends to present with more prominent bulbar symptoms — difficulty swallowing, speaking, and facial weakness — and often responds less well to conventional treatments like cholinesterase inhibitors.

3. Anti-LRP4 Antibodies (~1–3% of MG patients)

A small number of patients have antibodies targeting LRP4 (low-density lipoprotein receptor-related protein 4), the receptor that sits upstream of MuSK in the agrin signaling pathway. LRP4 is the initial docking point for agrin, so antibodies against LRP4 block the very first step in the signaling cascade that maintains AChR clustering. The downstream consequence is similar to anti-MuSK disease: impaired receptor organization and weakened transmission.

Anti-LRP4 MG is the least well-characterized of the three subtypes and tends to present with milder symptoms, though research on this group is still evolving.

*Note (intricacies): There is also a subset of MG patients — roughly 5–10% — who are “seronegative,” meaning none of the standard antibody tests come back positive. Some of these individuals may have low-titer antibodies below the detection threshold of current assays, or antibodies against targets that have not yet been identified. Seronegative MG remains an active area of research.

Why the Weakness Fluctuates

One of the most distinctive clinical features of myasthenia gravis is that the weakness is fatigable. Patients are often stronger in the morning and weaker by evening, or they may be able to perform a movement once but struggle to repeat it.

This pattern is a direct consequence of what is happening at the neuromuscular junction. Under normal conditions, the safety margin means that even if some ACh molecules fail to find a receptor or some receptors are unavailable, there are still enough successful binding events to generate a contraction. In MG, the safety margin is severely reduced because so many receptors have been destroyed, blocked, or disorganized.

During the first contraction, the amount of ACh released may still be sufficient to activate the remaining receptors and produce a normal-appearing movement. But with each subsequent stimulation, the nerve terminal releases slightly less ACh — a normal physiological phenomenon called presynaptic rundown. In a healthy person, this doesn’t matter because the safety margin compensates for it. In an MG patient, the already-thin margin disappears, and successive contractions produce weaker and weaker responses.

This is why repetitive nerve stimulation testing, a common electrophysiological study used to diagnose MG, shows a characteristic decremental response: the electrical response of the muscle gets smaller with each repeated stimulus.

The Thymus Connection

The thymus gland plays a significant and somewhat unusual role in myasthenia gravis. The thymus is a small organ located behind the sternum that is most active during childhood and normally shrinks (involutes) with age. Its primary function is the maturation and selection of T cells, a type of immune cell. During this process, the thymus is supposed to eliminate T cells that would react against the body’s own proteins — a process called central tolerance.

In approximately 60–70% of MG patients with anti-AChR antibodies, the thymus is abnormal. About 10–15% of these patients have a thymoma, an actual tumor of the thymus. The remaining patients often show thymic hyperplasia, in which the thymus contains active germinal centers — structures normally found in lymph nodes where immune responses are generated. These germinal centers within the thymus are thought to be sites where the autoimmune response against AChR is initiated and sustained, essentially acting as a factory for the antibodies that drive the disease.

This is why thymectomy — surgical removal of the thymus — has been a treatment option for MG, particularly in patients with thymoma or generalized anti-AChR MG. The rationale is that removing the source of the aberrant immune response can reduce antibody production and improve symptoms over time.

*Note about thymoma and MG (intricacies): The relationship between thymoma and MG is paradoxical. The thymus is supposed to teach the immune system what not to attack. In thymoma-associated MG, the tumor disrupts normal thymic selection, allowing autoreactive T cells that recognize AChR to escape into the circulation. Interestingly, not all patients with thymoma develop MG, and not all MG patients with thymoma improve after resection. The thymoma itself may alter the immune repertoire in ways that persist even after the tumor is removed. Additionally, thymoma-associated MG can sometimes be accompanied by other autoimmune conditions, suggesting a broader failure of self-tolerance rather than a defect specific to neuromuscular junction proteins.

Current Treatment Approaches

Treatment for myasthenia gravis generally targets either the symptoms or the underlying immune dysfunction.

Cholinesterase inhibitors, such as pyridostigmine, are typically the first line of symptomatic treatment. They work by inhibiting the enzyme acetylcholinesterase, which normally breaks down ACh in the synaptic cleft. By slowing ACh degradation, these drugs increase the amount of ACh available to bind to the remaining functional receptors, partially compensating for the receptor deficit. They do not address the underlying autoimmune process.

Immunosuppressive therapies form the backbone of long-term disease management. Corticosteroids and steroid-sparing agents such as azathioprine, mycophenolate mofetil, and tacrolimus are used to broadly suppress the immune system’s production of the pathogenic antibodies. These treatments are effective but come with significant side effects related to chronic immunosuppression.

More recently, targeted biological therapies have entered the landscape. Rituximab, a monoclonal antibody that depletes B cells (the immune cells that produce antibodies), has shown particular efficacy in anti-MuSK MG. Complement inhibitors such as eculizumab and ravulizumab directly block the complement cascade that damages the postsynaptic membrane in anti-AChR MG. Neonatal Fc receptor (FcRn) inhibitors such as efgartigimod work by accelerating the clearance of IgG antibodies from the bloodstream, rapidly reducing the circulating pathogenic antibody levels.

*Note about myasthenic crisis (intricacies): Myasthenic crisis is a life-threatening complication in which respiratory muscles become too weak to maintain adequate breathing. It can be triggered by infection, surgery, medication changes, or stress. Crisis requires emergency treatment, typically with plasma exchange (which physically removes circulating antibodies from the blood) or intravenous immunoglobulin (IVIg, which modulates the immune response through mechanisms that are still not fully understood). These are rapid-acting interventions used as bridges while longer-term immunotherapy takes effect.